TD Cowen maintains Gilead Sciences at Buy, raises price target to $175 from $160
TD Cowen kept Gilead Sciences' rating at Buy and increased its price target to $175 from $160, suggesting a 5.7% upside from the Oct 29 close of $165.61. Recent analyst price targets for Gilead range from $131 to $190.
How this was made
The 30-second read
Why it matters
The upgrade signals confidence in Gilead's near‑term performance, potentially prompting modest buying.
Market read
Analyst target raise provides a fresh catalyst for GILD, offering a modest trade idea.
What to watch
Upcoming regulatory decisions on Gilead's key drugs could materially affect the stock beyond the analyst's target.
Background
TD Cowen's price target adjustment follows recent analyst activity on Gilead, with targets ranging $131‑$190.
Ticker impact
TD Cowen raised its price target on Gilead Sciences to $175 from $160, indicating a fresh analyst upgrade.
likely upward pressure as the market incorporates the higher target
The new $175 target implies a 5.7% upside from the recent close, prompting short‑term buying interest.
Market effects
May boost sentiment in the broader biotech sector as peers see potential for higher valuations.
Limited to US markets where GILD trades; no notable regional effect.
Minor, confined to investors tracking Gilead and related biotech funds.
Counterpoint
Some investors may view the target raise as insufficient given Gilead's pipeline, preferring a larger upside.
Key entities
- AnalystTD Cowen
Equity research firm that raised Gilead's price target.
- CompanyGilead Sciences
Biopharmaceutical company subject of the analyst upgrade.
